Effect of simvastatin on the lipid profile of hemodialysis patients.
BACKGROUND
Simvastatin, a 3-hydroxy 3-methylglutaryl co-enzyme A (HMG-CoA) reductase inhibitor, is used widely for treatment of hypercholesterolemia. Simvastatin may be a suitable treatment for dyslipidemia in hemodialysis (HD) patients. However, investigation of the side-effects and safety of long-term administration of simvastatin to HD patients has been limited. In this study, we investigated the effects and safety of simvastatin and its effects on lipoprotein metabolism in hypercholesterolemic patients on HD.


METHODS
Simvastatin was administered at a dosage of 5 mg/day for 24 weeks to 38 HD patients with high serum total cholesterol (TC) levels (200 mg/dl) or low high-density lipoprotein cholesterol (HDL-C) levels (35 mg/dl). Every four weeks, serum lipids, apolipoprotein, lipoprotein (a) [Lp(a)] and malondialdehyde (MDA) levels were measured. In addition, lipid levels were determined in each lipoprotein fraction separated by ultracentrifugation.


RESULTS
After 24 weeks of simvastatin administration, TC significantly decreased by 25.7%, and low-density lipoprotein cholesterol (LDL-C) was significantly decreased by 33.6%. Triglyceride (TG) and HDL-C showed no significant changes. Apolipoprotein (apo) B significantly decreased by 24.5% and apo E by 30.0%. No significant changes were observed in the other apolipoproteins. MDA was also significantly decreased, whereas Lp(a) was not significantly altered. In the lipoprotein fractions, very LDL cholesterol (VLDL-C), intermediate-density lipoprotein cholesterol (IDL-C), LDL1 cholesterol (LDL1-C), and LDL2 cholesterol (LDL2-C) showed significant decreases. No particular side-effects were observed during the 12 months of simvastatin administration.


CONCLUSIONS
These results suggest that simvastatin appears to be safe and effective in HD patients with hypercholesterolemia.
Nishikawa
O
O
Shouseikai Nishide Hospital, Kaizuka, Japan.
Mune
M
M
Miyano
M
M
Nishide
T
T
Nishide
I
I
Maeda
A
A
Kimura
K
K
Takahashi
T
T
Kishino
M
M
Tone
Y
Y
Otani
H
H
Ogawa
A
A
Maeda
T
T
Yukawa
S
S
D000368:Aged; D001055:Apolipoproteins B / Q000097:blood / Q000187:drug effects; D001057:Apolipoproteins E / Q000097:blood / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D015243:Cholesterol, VLDL / Q000097:blood / Q000187:drug effects; D003402:Creatine Kinase / Q000097:blood / Q000187:drug effects; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy; D008055:Lipids / Q000097:blood*; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008875:Middle Aged; D006435:Renal Dialysis; D019821:Simvastatin / Q000627:therapeutic use*; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
D001055:Apolipoproteins B; D001057:Apolipoproteins E; D015243:Cholesterol, VLDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D014280:Triglycerides; D008315:Malondialdehyde; D002784:Cholesterol; D019821:Simvastatin; D003402:Creatine Kinase